After a year marked by dramatic…
After a year marked by dramatic ups and downs, William [...]
Zealand Pharma may be gearing up…
Zealand Pharma may be gearing up for a high-stakes year [...]
A key late-stage trial of Arcus…
A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT [...]
Cycle Pharmaceuticals is circling…
Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare [...]
Rezolute’s stock has plunged 87%…
Rezolute’s stock has plunged 87% after the company’s rare disease [...]
Eli Lilly has surpassed…
Eli Lilly has surpassed analysts’ highest hopes for the efficacy [...]
Moderna has tapped Swedish…
Moderna has tapped Swedish long-acting drug formulation company Nanexa to [...]
Barreling toward the end of its…
Barreling toward the end of its cash runway, GRI Bio [...]
OTR may still be keeping its own…
OTR may still be keeping its own pipeline under wraps, [...]
Two affiliates of Apple Tree…
Two affiliates of Apple Tree Partners have filed for bankruptcy, [...]